Price Alert

Adaptimmune Therapeutics (ADAP)

NASDAQ: ADAP · Real-Time Price · USD

0.28

-0.00 (-1.06%)

At close: Jun 09, 2025, 3:58 PM

Adaptimmune Therapeutics Statistics

Share Statistics

Adaptimmune Therapeutics has 257.85M shares outstanding. The number of shares has increased by 501.05% in one year.

Shares Outstanding	257.85M
Shares Change (YoY)	501.05%
Shares Change (QoQ)	500.14%
Owned by Institutions (%)	8.11%
Shares Floating	228.64M
Failed to Deliver (FTD) Shares	440,479
FTD / Avg. Volume	23.98%

Short Selling Information

The latest short interest is 5.83M, so 2.2% of the outstanding shares have been sold short.

Short Interest	5.83M
Short % of Shares Out	2.2%
Short % of Float	2.67%
Short Ratio (days to cover)	2.29

Valuation Ratios

The PE ratio is -1.92 and the forward PE ratio is -2.04. Adaptimmune Therapeutics's PEG ratio is 0.04.

PE Ratio	-1.92
Forward PE	-2.04
PS Ratio	0.76
Forward PS	0.3
PB Ratio	11.47
P/FCF Ratio	-1.79
PEG Ratio	0.04

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Adaptimmune Therapeutics.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.92, with a Debt / Equity ratio of 6.26.

Current Ratio	2.92
Quick Ratio	2.8
Debt / Equity	6.26
Debt / EBITDA	-1.41
Debt / FCF	-0.98
Interest Coverage	-20.54

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$351.84K
Profits Per Employee	$-139.95K
Employee Count	506
Asset Turnover	0.72
Inventory Turnover	0.01

Taxes

Income Tax	3.58M
Effective Tax Rate	-5.32%

Stock Price Statistics

The stock price has increased by -72.55% in the last 52 weeks. The beta is 2.25, so Adaptimmune Therapeutics's price volatility has been higher than the market average.

Beta	2.25
52-Week Price Change	-72.55%
50-Day Moving Average	0.27
200-Day Moving Average	0.61
Relative Strength Index (RSI)	50.01
Average Volume (20 Days)	1,836,844

Income Statement

In the last 12 months, Adaptimmune Therapeutics had revenue of 178.03M and earned -70.81M in profits. Earnings per share was -0.28.

Revenue	178.03M
Gross Profit	177.96M
Operating Income	-68.76M
Net Income	-70.81M
EBITDA	-52.66M
EBIT	-63.89M
Earnings Per Share (EPS)	-0.28

Full Income Statement

Balance Sheet

The company has 91.14M in cash and 74.21M in debt, giving a net cash position of 16.93M.

Cash & Cash Equivalents	91.14M
Total Debt	74.21M
Net Cash	16.93M
Retained Earnings	-1.09B
Total Assets	158.07M
Working Capital	51.93M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -73.21M and capital expenditures -2.72M, giving a free cash flow of -75.93M.

Operating Cash Flow	-73.21M
Capital Expenditures	-2.72M
Free Cash Flow	-75.93M
FCF Per Share	-0.05

Full Cash Flow Statement

Margins

Gross margin is 99.96%, with operating and profit margins of -38.62% and -39.78%.

Gross Margin	99.96%
Operating Margin	-38.62%
Pretax Margin	-37.77%
Profit Margin	-39.78%
EBITDA Margin	-29.58%
EBIT Margin	-38.62%
FCF Margin	-42.65%

Dividends & Yields

ADAP does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for ADAP is $1.4, which is 400% higher than the current price. The consensus rating is "Buy".

Price Target	$1.4
Price Target Difference	400%
Analyst Consensus	Buy
Analyst Count	6

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	-9.69
Piotroski F-Score	2